TECHNOLOGY

Accurins™

BIND is discovering and developing AccurinsTM, proprietary new best-in-class therapeutics with superior target selectivity, and an improved therapeutic index.

Leveraging our proprietary Medicinal Nanoengineering® platform, we develop Accurins that outperform conventional systemic drugs by selectively accumulating in diseased tissues and cells. The result is higher drug concentrations at the site of action with minimal off-target exposure, leading to markedly better efficacy and safety.

Accurin Components

BIND's targeted Accurins consist of the following components that facilitate selective targeting of diseased cells and tissues:

• Targeting ligand: The ability to attach targeting ligands to nanoparticles is a unique and valuable aspect of our technology. We develop targeting ligands that recognize specific disease-associated cell-surface proteins or receptors, enabling Accurins to preferentially accumulate at their intended site of action.
  
• Stealth and protective layer: Engineered using proprietary methods for precisely controlling the Accurin surface characteristics, the stealth and protective layer shields targeted nanoparticles from immune surveillance, while providing attachment sites for the targeting ligand through proprietary linking chemistries.
  
• Therapeutic payload (API): We can incorporate a broad range of active pharmaceutical ingredients into our targeted nanoparticles, including small molecules, peptides, proteins, and nucleic acids, such as siRNA.
  
• Controlled-release polymers: The API payload is encapsulated in a matrix of clinically validated, biodegradable, and biocompatible polymers that mediate the release of the payload at the site of disease at an optimal rate.